Showing 1-10 of 13 results for "".
- Hypertrophic cardiomyopathy: making the diagnosishttps://pace-cme.org/meeting-reports/innovative-therapeutic-approaches-in-hypertrophic-cardiomyopathy/hypertrophic-cardiomyopathy-making-the-diagnosis/17595/10' education - Sep. 28, 2022 - Michelle Michels, MD, PhD
- Unhiding hypertrophic cardiomyopathy, a call for actionhttps://pace-cme.org/meeting-reports/innovative-therapeutic-approaches-in-hypertrophic-cardiomyopathy/unhiding-hypertrophic-cardiomyopathy-a-call-for-action/17594/10' education - Sep. 28, 2022 - Antonis Pantazis, MD
- Managing patients with hypertrophic cardiomyopathy: what is the therapeutic landscape?https://pace-cme.org/meeting-reports/innovative-therapeutic-approaches-in-hypertrophic-cardiomyopathy/managing-patients-with-hypertrophic-cardiomyopathy-what-is-the-therapeutic-landscape/17597/10' education - Sep. 30, 2022 - Prof. Iacopo Olivotto, MD
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
https://pace-cme.org/programs/acc-action-center/targeting-cardiac-energetics-with-cardiac-mitotrope-in-nonobstructive-hcm/24346/ACC.24 - There is an unmet treatment need for nonobstructive hypertrophic cardiomyopathy (nHCM). Martin Maron shares the results of IMPROVE-HCM, which evaluated the efficacy and safety of the novel cardiac mitotrope ninerafaxstat in nHCM.Mavacamten in symptomatic non-obstructive HCM
https://pace-cme.org/congress-coverage/esc-congress-2025/mavacamten-in-symptomatic-non-obstructive-hcm/37860/ESC Congress 2025 – Milind Desai discusses results from the ODYSSEY-HCM trial, which found that mavacamten did not improve peak oxygen uptake or symptoms at 48 weeks in patients with symptomatic non-obstructive hypertrophic cardiomyopathy compared with placebo.- Cardiac myosin inhibitor reduces need for septal reduction therapy in obstructive HCMhttps://pace-cme.org/congress-coverage/acc22/cardiac-myosin-inhibitor-reduces-need-for-septal-reduction-therapy-in-obstructive-hcm/17498/3' education - Apr. 2, 2022 - Prof. Milind Desai, MD
- Emerging therapies in HCM: The potential role of cardiac myosin inhibitorshttps://pace-cme.org/topics/hypertrophic-cardiomyopathy/emerging-therapies-in-hcm-the-potential-role-of-cardiac-myosin-inhibitors/17528/10' education - May 4, 2022 - Ahmad Masri, MD and prof. Deepak Bhatt, MD
- Impact of new first-in-class medical therapy in obstructive HCMhttps://pace-cme.org/topics/hypertrophic-cardiomyopathy/impact-of-new-first-in-class-medical-therapy-in-obstructive-hcm/17500/3' education - Apr. 3, 2022 - Joseph Cleveland, MD
- Cardiac myosin inhibitor is safe and effective in HCM in phase 2 trialhttps://pace-cme.org/congress-coverage/esc-heart-failure-2023/cardiac-myosin-inhibitor-is-safe-and-effective-in-hcm-in-phase-2-trial/17702/3' education - June 1, 2023 - Ahmad Masri, MD
- Cardiac myosin inhibitor sustainably reduces LVOT gradient in HCMhttps://pace-cme.org/topics/hypertrophic-cardiomyopathy/cardiac-myosin-inhibitor-sustainably-reduces-lvot-gradient-in-hcm/17504/3' education - Apr. 4, 2022 - Maya Guglin, MD, PhD
- Prev
- Next